Vistagen Therapeutics, Inc. (VTGN) Dividend History

Company News

• All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy

  VistaGen Therapeutics (VTGN) has received a rating upgrade to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates, which is a powerful force impacting stock prices. The upgrade positions the company in the top 20% of Zacks-covered stocks in terms of estimate revisions, suggesting the stock might move higher in the near term.

  Benzinga
• Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?

  The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research
• Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

  Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research
• How Vistagen (VTGN) Stock Stands Out in a Strong Industry

  Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  Zacks Investment Research
• Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

  William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.  The lead product Fasedienol (PH94B), is an intranasal pherine and is in late-stage development for SAD, which affects about 10% of the U.S. population, with 6 million adults being treated by a physician. Related Content: Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst. Aside from one negative Phase 3 study, PALISADE-1, which was ...Full story available on Benzinga.com

  Benzinga